Dizziness cannabinoids

I. 18-1.62), number-needed-to-treat (NNT) was 6 for complete control of nausea relative risk was 1.28 (Cl 1.08-1.51), NNT 8 for complete control of vomiting. Cannabinoids were not more effective in patients receiving very low or very high emetogenic chemotherapy. In crossover trials, patients preferred cannabinoids for future chemotherapy cycles relative risk 2.39 (2.05-2.78), NNT 3. Some potentially beneficial side effects occurred more often with cannabinoids high 10.6 (6.86-16.5), NNT 3 sedation or drowsiness 1.66 (1.46-1.89), NNT 5 euphoria 12.5 (3-52.1), NNT 7. Harmful side effects also occurred more often with cannabinoids dizziness 2.97 (2.31-3.83), NNT 3 dysphoria or depression 8.06 (3.38-19.2), NNT 8 hallucinations 6.10 (2.41-15.4), NNT 17 paranoia 8.58 (6.38-... 

Cannabinoids have antiemetic activity when used alone or in combination with other antiemetics.5 Dronabinol and nabilone are commercially available oral formulations used for preventing and treating refractory CINV.5,10 Dronabinol is also used to treat anorexia and weight loss associated with human immunodeficiency virus (HIV) infection. Cannabinoids are thought to exert their antiemetic effect centrally, although the exact mechanism of action is unknown.1,10 Sedation, euphoria, hypotension, ataxia, dizziness, and vision difficulties can occur with cannabinoids. 

Rash central nervous system symptoms (insomnia, irritability, lethargy, dizziness, vivid dreams) usually resolve in 2 weeks increased LFTs false-positive cannabinoid test teratogenic in monkeys... 

Two long-term effects are theoretical considerations. One is that exposure to the cannabinoids may somehow have caused a chronic or delayed posttraumatic stress disorder. In the dosage and frequency used, this is unlikely. The postexperimental effect that was most undesirable was postural hypotension. This resulted in dizziness and faintness, from which all subjects recovered. Such a stress is Insufficient to provoke a delayed or chronic posttraumatlc stress syndrome, nor is there any evidence that any such syndrome occurred. 

CB1 and CB2 can be found throughout the human body hence, there are a variety of ways that cannabinoids can physically and psychologically affect the body s systems. As an example, the presence of CB1 receptors in the eye may explain how marijuana eases glaucoma and relieves intraocular pressure. Other research indicates that THC can block receptors in the brain and body to produce dizziness, dry mouth, and altered depth perception— all common effects of marijuana use. There appears to be an... 

In our 1987 review, we summarized the research and clinical experience in this area [1], Surprisingly, in spite of the enormous public interest in medical marijuana and countless articles in the daily press and magazines focused predominantly on this aspect of marijuana use, little progress has been reported on the antiemetic activity of cannabinoids in the last decade. Plasse et al. have reviewed the clinical experience gained over 7 years with dronabinol (d9-THC) in antiemetic treatment [117]. With doses of 7 mg/m2 or below, complete response was noted in 36% of the patients, 32% showed partial response and 32% showed no response. However, 65% displayed drowsiness and dizziness and 12% had dysphoric effects. Combination treatment of dronabinol with prochlorperazine (a dopamine receptor blocker widely used as an antipsychotic drug with antiemetic effects) was more effective than each drug alone [118]. 

Nabilone is a synthetic cannabinoid and has properties similar to tetrahydrocannabinol (the active constituent of marijuana) which has an antiemetic action. It is used to relieve nausea or vomiting caused by cytotoxic drugs. Adverse effects include somnolence, dry mouth, decreased appetite, dizziness, euphoria, dysphoria, postural hypotension, confusion and psychosis. These may be reduced if prochlorperazine is given concomitantly. 

The cannabinoids act on the cerebral cortex and have the same side effects and adverse reactions as antihistamines and anticholinergic. These include drowsiness, dry mouth, blurred vision, tachycardia, and constipation. Caimabinoids include dronabinol and nabilone. These drugs should not be administered to glaucoma patients because they dilate the pupils (mydriasis). They are contraindicated for use in patients with psychiatric disorders and also used as an appetite stimulant for patients with AIDS. Side effects include mood changes, euphoria, drowsiness, dizziness, headaches, depersonalization, nightmares, confusion, incoordination, memoiy lapse, dry mouth, orthostatic hypotension, hypertension, and tachycardia. Less common symptoms include depression, anxiety, and manic psychosis. 

Restlessness, dizziness, giddiness, failure to obey orders, confusion, erratic behavior, stumbling or staggering, vomiting Anticholinergics, indoles, cannabinoids, anxiety reaction, other intoxications (such as alcohol, bromides, lead, barbiturates)... 

Euphoria, relaxation, day-dreaming, unconcerned attitude, easy laughter, hypotension and dizziness onsudden standing Cannabinoids... 

The most common adverse events with cannahi-noids are CNS-related, including dizziness, drowsiness, persistent appetite stimulation, conjunctival hyperemia, dry mouth, and the euphoria associated with the cannabinoid high . Some of the less common adverse events associated with each individual cannabinoid agonist are listed in Table 125.1. 

Adverse events observed with nonselective agonists may not be as common or pronounced with peripherally selective CB cannabinoids. They include potential for abuse, confusion, ataxia, memory loss, psychosis, dizziness, hypotension, sedation, euphoria, paranoia, and dry mouth. Less common adverse events include orthostatic hypotension, abdominal pain, nausea, vomiting, anxiety, myalgias, increased appetite, nightmares, flushing, visual difficulties, and headache. No specific antagonists are currently in use, but adverse effects can be cared for individually. 

---